Cantor Fitzgerald initiated coverage on Acumen Pharmaceuticals with a new price target
$ABOS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals with a rating of Overweight and set a new price target of $13.00